OMEROS CORP (OMER) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth No data.
31/70
2.2 / 5 stars
All 70 Win/Lose results and 50 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 2 wins, 5 losses, 5 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseOMER / S&P -9.94% / 15.20% |
No dataOMER / S&P / 15.00% |
LoseOMER / S&P -181.13% / 50.40% |
| 2026-Q10/2 |
LoseOMER / S&P -38.53% / -4.33% |
No dataOMER / S&P / 11.30% |
LoseOMER / S&P -142.86% / 27.70% |
| 2025-Q41/2 |
WinOMER / S&P 319.02% / 2.65% |
No dataOMER / S&P / 9.00% |
LoseOMER / S&P -97.79% / 13.40% |
| 2025-Q31/1 |
WinOMER / S&P 36.67% / 8.12% |
No dataOMER / S&P / 4.61% |
No dataOMER / S&P / 13.45% |
| 2025-Q20/1 |
LoseOMER / S&P -63.50% / 10.94% |
No dataOMER / S&P / 4.83% |
No dataOMER / S&P / 10.63% |
| 2025-Q10/1 |
LoseOMER / S&P -16.80% / -4.27% |
No dataOMER / S&P / 4.98% |
No dataOMER / S&P / 10.57% |
| 2024-Q41/1 |
WinOMER / S&P 148.87% / 2.41% |
No dataOMER / S&P / 5.25% |
No dataOMER / S&P / 6.15% |
| 2024-Q30/1 |
LoseOMER / S&P -2.22% / 5.89% |
No dataOMER / S&P / 5.89% |
No dataOMER / S&P / 6.11% |
| 2024-Q21/1 |
WinOMER / S&P 17.68% / 4.28% |
No dataOMER / S&P / 5.38% |
No dataOMER / S&P / 5.12% |
| 2024-Q10/1 |
LoseOMER / S&P 5.50% / 10.56% |
No dataOMER / S&P / 5.71% |
No dataOMER / S&P / 5.59% |
| 2023-Q41/1 |
WinOMER / S&P 11.99% / 11.69% |
No dataOMER / S&P / 6.81% |
No dataOMER / S&P / 7.78% |
| 2023-Q30/1 |
LoseOMER / S&P -46.32% / -3.27% |
No dataOMER / S&P / 7.52% |
No dataOMER / S&P / -5.03% |
| 2023-Q21/2 |
WinOMER / S&P 16.99% / 8.74% |
No dataOMER / S&P / 9.50% |
LoseOMER / S&P -79.23% / -8.57% |
| 2023-Q11/2 |
WinOMER / S&P 105.75% / 7.50% |
No dataOMER / S&P / 10.77% |
LoseOMER / S&P -76.27% / -15.69% |
| 2022-Q40/2 |
LoseOMER / S&P -28.25% / 7.56% |
No dataOMER / S&P / 11.88% |
LoseOMER / S&P -75.64% / -17.99% |
| 2022-Q31/2 |
WinOMER / S&P 14.55% / -4.88% |
No dataOMER / S&P / 13.47% |
LoseOMER / S&P -261.31% / -1.41% |
| 2022-Q20/2 |
LoseOMER / S&P -54.24% / -16.10% |
No dataOMER / S&P / 13.71% |
LoseOMER / S&P -236.68% / 11.04% |
| 2022-Q10/2 |
LoseOMER / S&P -6.53% / -4.60% |
No dataOMER / S&P / 15.97% |
LoseOMER / S&P -229.51% / 42.23% |
| 2021-Q40/1 |
LoseOMER / S&P -53.37% / 11.03% |
No dataOMER / S&P / 15.00% |
No dataOMER / S&P / 96.40% |
| 2021-Q30/2 |
LoseOMER / S&P -7.08% / 0.58% |
LoseOMER / S&P -6.29% / 10.77% |
No dataOMER / S&P / 69.42% |
| 2021-Q20/2 |
LoseOMER / S&P -16.63% / 8.55% |
LoseOMER / S&P -13.66% / 6.58% |
No dataOMER / S&P / 51.81% |
| 2021-Q11/2 |
WinOMER / S&P 24.56% / 6.17% |
LoseOMER / S&P -37.18% / -1.06% |
No dataOMER / S&P / 7.39% |
| 2020-Q41/2 |
WinOMER / S&P 41.35% / 12.15% |
LoseOMER / S&P -33.98% / -3.72% |
No dataOMER / S&P / -33.42% |
| 2020-Q30/2 |
LoseOMER / S&P -31.32% / 8.93% |
LoseOMER / S&P -3.79% / -2.04% |
No dataOMER / S&P / -27.10% |
| 2020-Q21/2 |
LoseOMER / S&P 10.10% / 20.54% |
WinOMER / S&P 33.51% / -0.46% |
No dataOMER / S&P / -27.11% |
| 2020-Q12/2 |
WinOMER / S&P -5.11% / -19.60% |
WinOMER / S&P 126.86% / 3.47% |
No dataOMER / S&P / -14.75% |
| 2019-Q41/2 |
LoseOMER / S&P -13.72% / 9.07% |
WinOMER / S&P 274.34% / 5.36% |
No dataOMER / S&P / 2.99% |
| 2019-Q32/2 |
WinOMER / S&P 4.08% / 1.70% |
WinOMER / S&P 364.62% / 5.02% |
No dataOMER / S&P / 0.21% |
| 2019-Q21/2 |
LoseOMER / S&P -9.67% / 4.30% |
WinOMER / S&P 94.40% / 6.64% |
No dataOMER / S&P / 8.65% |
| 2019-Q11/2 |
WinOMER / S&P 55.92% / 13.65% |
LoseOMER / S&P -7.57% / 8.12% |
No dataOMER / S&P / 14.29% |
| 2018-Q40/2 |
LoseOMER / S&P -54.36% / -13.52% |
LoseOMER / S&P -53.93% / 9.05% |
No dataOMER / S&P / 18.23% |
| 2018-Q31/2 |
WinOMER / S&P 34.56% / 7.71% |
LoseOMER / S&P -66.22% / 10.21% |
No dataOMER / S&P / 19.06% |
| 2018-Q21/2 |
WinOMER / S&P 62.40% / 3.43% |
LoseOMER / S&P -27.88% / 9.03% |
No dataOMER / S&P / 14.46% |
| 2018-Q11/2 |
LoseOMER / S&P -42.51% / -0.76% |
WinOMER / S&P 16.58% / 7.68% |
No dataOMER / S&P / 12.46% |
| 2017-Q41/2 |
LoseOMER / S&P -10.13% / 6.64% |
WinOMER / S&P 55.77% / 7.03% |
No dataOMER / S&P / 13.82% |
| 2017-Q32/2 |
WinOMER / S&P 8.59% / 4.48% |
WinOMER / S&P 80.78% / 5.68% |
No dataOMER / S&P / 17.57% |
| 2017-Q22/2 |
WinOMER / S&P 31.68% / 3.09% |
WinOMER / S&P 95.94% / 4.83% |
No dataOMER / S&P / 17.74% |
| 2017-Q12/2 |
WinOMER / S&P 52.42% / 6.07% |
WinOMER / S&P 126.17% / 3.67% |
No dataOMER / S&P / 13.32% |
| 2016-Q41/2 |
LoseOMER / S&P -11.11% / 3.82% |
WinOMER / S&P 208.07% / 2.09% |
No dataOMER / S&P / 7.05% |
| 2016-Q32/2 |
WinOMER / S&P 6.08% / 3.85% |
WinOMER / S&P 404.52% / 0.20% |
No dataOMER / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OMER total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 362.74% | 20.78% |
| Annualized return | 362.74% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OMER total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 20.31% | 83.14% |
| Annualized return | 3.77% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | OMER total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 78.90% | 319.30% |
| Annualized return | 5.99% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |